Palbociclib price in Malaysia (2026)

There is no fixed public retail price for palbociclib in Malaysia in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 400–BDT 400 (US$3.26–US$3.26) per unit, about MYR 13.28–MYR 13.28 in MYR per unit and MYR 398.47–MYR 398.47 per 30-unit month, before freight, customs duty and distributor margin.

Yes, but only through the rules of the National Pharmaceutical Regulatory Agency (NPRA): Malaysia has one of the better-regulated generics markets in ASEAN: products must be registered with the NPRA with a valid product licence, and hospital procurement runs through government tenders. Patient-level imports of unregistered products require an NPRA import authorisation. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.

We cannot confirm the registration status of every individual generic brand in Malaysia. National Pharmaceutical Regulatory Agency (NPRA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.

Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.

Malaysia: marketed. Palbociclib is named by NPRA in its CDK4/6 inhibitor safety alert as a CDK4/6 inhibitor used in Malaysia, indicating it is on the Malaysian market